TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04423627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00416676
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04143984
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
Study: NCT05814042
Drug: Next Generation ORS (oral rehydration solution) (including placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition used to stop diarrhea
Study: NCT05814042
Drug: Current standard control ORS (oral rehydration solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: current standard control ORS in diarrheic patients with cholera
Study: NCT05720026
Drug: SYSA1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
Study: NCT05919095
Drug: Carrilizumab plus GEMOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment.
Study: NCT06273111
Drug: 5% simvastatin ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
Study: NCT05099107
Drug: Salbutamol Only Product in Oral Dose Form
Normalized name: Salbutamol only product in oral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken 3 times daily for 6 months
Study: NCT04723563
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
Study: NCT05046431
Drug: BAT2506
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg/0.5mL
Study: NCT05923411
Drug: Single dose of PF-07220060 as second Tablet Formulation
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
Study: NCT05923411
Drug: Single dose of PF-07220060 as second Tablet Formulation
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
Study: NCT05923411
Drug: Single dose of PF-07220060 as a Tablet Formulation
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07220060 as a tablet formulation administered under fed conditions
Study: NCT05923411
Drug: Single dose of PF-07220060 as third tablet formulation
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
Study: NCT06498089
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.
Study: NCT04711356
Drug: Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
Study: NCT06619288
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
Study: NCT06619288
Drug: TDF+3TC+EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
Study: NCT06619288
Drug: DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
Study: NCT05921305
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
Study: NCT05069311
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery
Study: NCT04588207
Drug: Urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day.
Study: NCT05069311
Drug: Conventional intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
Study: NCT05260385
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC1036 are administered orally QD or BID in 21-day cycles.
Study: NCT05537558
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
Study: NCT04005534
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Study: NCT04005534
Drug: Preemptive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Study: NCT06619678
Drug: MK-8507
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06249854
Drug: Bojungikki-tang(BJIKT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects
Study: NCT06281353
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCA 90%
Study: NCT01228110
Drug: Hydrocortison
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04981431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05479591
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
Study: NCT06003465
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06431685
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
Study: NCT04572165
Drug: Ozempic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT05320107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl
Study: NCT05136144
Drug: SM-020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Akt Inhibitor SM-020 Gel
Study: NCT04875026
Drug: 5-fluorouracil 4% (Tolak)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Tolak once daily in the evening for 4 weeks
Study: NCT06199011
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
Study: NCT05976308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
Study: NCT05523141
Drug: ASC10
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner
Study: NCT05523141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner
Study: NCT01825083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % normal saline group receives same volume as the ketamine dose
Study: NCT05735379
Drug: Deprescribing anticholinergic and sedative mediications
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
Study: NCT04989972
Drug: PSIL428
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of psilocybin
Study: NCT04989972
Drug: PSIL428
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg psilocybin
Study: NCT05823714
Drug: VEN+AZA+Modified BUCY
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days.
Study: NCT05556564
Drug: observational study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention, observational study
Study: NCT05691244
Drug: Drug: Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
Study: NCT05691244
Drug: Sovateltide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
Study: NCT05610800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
Study: NCT05008809
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
Study: NCT04932746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
Study: NCT05954247
Drug: DWC202216
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202216
Study: NCT01223053
Drug: Ketoprofen 10% cream
Normalized name: KETOPROFEN 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
Study: NCT01223053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
Study: NCT05866367
Drug: Low dose Regular Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin administered intranasally at either 40 IU
Study: NCT05866367
Drug: High dose Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin administered intranasally at either 80 IU
Study: NCT06245122
Drug: CS23546
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally.
Study: NCT04859660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
Study: NCT05347849
Drug: BPL-003
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of BPL-003 will be administered intranasally
Study: NCT04416737
Drug: Ultra-rapid insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
Study: NCT04765995
Drug: HZBio1 3mg / kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study: NCT04765995
Drug: HZBio1 6mg / kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study: NCT05198557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV placebo matched to inebilizumab.
Study: NCT04765995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered intramuscularly.
Study: NCT05536102
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/m2, day 1, q3w
Study: NCT05536102
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, days 1-14, q3w
Study: NCT05842330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm.
Study: NCT00517894
Drug: CEOP/IMVP-Dexa chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
Study: NCT05958771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
Study: NCT05047731
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
Study: NCT06250634
Drug: Vonoprazan + amoxicillin + clarithromycin
Normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
Study: NCT06260267
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension
Study: NCT06260267
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00041665
Drug: Recombinant Human Keratinocyte Growth Factor
Normalized name: Recombinant human keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03540355
Drug: Cipros 20 association
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once a day
Study: NCT04750902
Drug: 1.5% Arginine Dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study: NCT04750902
Drug: 4.0% Arginine Dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study: NCT04750902
Drug: 8.0% Arginine Dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study: NCT04981093
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml of normal saline was injected intravenously after induction of anesthesia
Study: NCT05046522
Drug: Palmitoylethanolamide sold as Levagen +
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
Study: NCT06262061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill orally BID x 14 days
Study: NCT06649448
Drug: TP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W).
Study: NCT04789928
Drug: Gentamicins-EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
Study: NCT00888680
Drug: BGC20-1531
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGC20-1531 administered orally
Study: NCT00888680
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT05882695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05073172
Drug: Topical Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically
Study: NCT03438526
Drug: Melatonin (Circadin ®)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
Study: NCT03438526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
Study: NCT06319846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
Study: NCT03817034
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
Study: NCT06241183
Drug: Oral Maalox/ Mylanta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive 30 ml Maalox/ Mylanta.
Study: NCT05155995
Drug: HCP2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05155995
Drug: RLD2007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05155995
Drug: RLD2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT04500665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06305910
Drug: Treatment with CD200AR-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
Study: NCT05651802
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
Study: NCT05006677
Drug: non-vitamin K antagonist oral anticoagulants (NOACs)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collecting information of patients with VT who received NOACs